Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Purchases $49,835.78 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Steven Chaouki purchased 40,849 shares of MAIA Biotechnology stock in a transaction dated Monday, December 22nd. The shares were bought at an average price of $1.22 per share, with a total value of $49,835.78. Following the completion of the acquisition, the director directly owned 151,873 shares of the company’s stock, valued at approximately $185,285.06. This represents a 36.79% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

MAIA Biotechnology Stock Performance

Shares of MAIA stock opened at $1.48 on Friday. The company has a market capitalization of $54.80 million and a price-to-earnings ratio of -2.03. MAIA Biotechnology, Inc. has a one year low of $0.87 and a one year high of $2.74. The company’s 50-day moving average is $1.21 and its 200 day moving average is $1.50.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Friday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.08). As a group, research analysts predict that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current fiscal year.

Institutional Trading of MAIA Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of MAIA. Centerpoint Advisory Group purchased a new position in shares of MAIA Biotechnology in the second quarter worth $28,000. Marshall Wace LLP purchased a new stake in shares of MAIA Biotechnology during the second quarter valued at $29,000. Jane Street Group LLC bought a new stake in MAIA Biotechnology in the 2nd quarter worth about $52,000. Geode Capital Management LLC raised its position in MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after buying an additional 7,746 shares during the last quarter. Finally, Centric Wealth Management lifted its stake in MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock valued at $1,032,000 after acquiring an additional 505,150 shares during the period. Institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.